Abstract
Acrocyanosis is a peripheral vascular disorder characterized by bluish discoloration of the distal extremities. While drug-induced acrocyanosis has been associated with selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, and other medications, venlafaxine has not previously been reported as a causative agent. We present a case of a 40-year-old female who developed acute acrocyanosis following the initiation of venlafaxine for insomnia. Symptoms appeared within 24 h of intake and progressively involved the hands and feet. Laboratory investigations were largely unremarkable, and other potential causes, including Raynaud's phenomenon and vasculitis, were excluded. Discontinuation of venlafaxine led to complete resolution of symptoms within a week, confirming a strong temporal association. This case underscores the need for clinical awareness of venlafaxine-induced acrocyanosis as a rare but possible adverse effect, emphasizing timely recognition and management to prevent complications.